Related Experiment Video
Updated: Sep 5, 2025
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Navneet Singh1, Sarah Temin2, Sherman Baker3
1Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Summary
Updated guidelines recommend specific targeted therapies for advanced non-small-cell lung cancer (NSCLC) with driver alterations. These evidence-based recommendations focus on anaplastic lymphoma kinase (ALK) and RET rearrangements for improved patient outcomes.
Area of Science:
- Oncology
- Genomics
- Clinical Guidelines
Background:
- Stage IV non-small-cell lung cancer (NSCLC) requires updated treatment strategies.
- Driver alterations in NSCLC necessitate targeted systemic therapies.
- Previous guidelines from ASCO and Ontario Health (Cancer Care Ontario) require revision.
Purpose of the Study:
- To update evidence-based recommendations for systemic therapy in stage IV NSCLC with driver alterations.
- To incorporate recent clinical trial data into treatment guidelines.
- To provide clinicians with current recommendations for targeted therapies.
Main Methods:
- Systematic review of randomized control trials (RCTs) from 2020-2021.
- Inclusion of two key studies informing the evidence base.
- Focus on efficacy and safety outcomes for treatment selection.
Main Results:
- For anaplastic lymphoma kinase (ALK) rearrangements in previously untreated NSCLC (PS 0-2), alectinib, brigatinib, or lorlatinib are recommended.
- Ceritinib or crizotinib are alternatives for ALK-rearranged NSCLC if preferred agents are unavailable.
- For RET rearrangements in previously untreated NSCLC (PS 0-2), selpercatinib or pralsetinib are options.
- Selpercatinib or pralsetinib are recommended for second-line treatment of RET-rearranged NSCLC.
Conclusions:
- Updated recommendations provide clear guidance on first- and second-line targeted therapies for specific driver alterations in NSCLC.
- The guideline emphasizes the use of specific tyrosine kinase inhibitors based on genetic profile.
- These recommendations aim to optimize treatment efficacy and safety for patients with advanced NSCLC.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K